News | June 16, 2014

Startup Company Targets Paradigm Shift in Heart Valve Surgery

The conventional tissue trileaflet heart valve (left) depicts much higher stresses compared to the new PolyNova valve (right).

June 16, 2014 — PolyNova, a startup company that has grown out of an inter-institutional collaboration between the University of Arizona (UA) and Stony Brook University, announced it is developing a novel polymeric prosthetic heart valve. Sarver Heart Center cardiologist Marvin J. Slepian, M.D., professor of medicine and biomedical engineering at the UA, is the founding CEO of the new venture. PolyNova entered an exclusive option to the patent rights jointly held by the two universities earlier this spring.

PolyNova plans to use synthetic biomaterials to create new valve replacement technologies for a new transcatheter aortic valve replacement (TAVR) procedure. The new materials and operation would allow surgeons to replace a diseased heart valve with a synthetic one via a catheter run inside the aorta, eliminating the need for open-heart surgery. 

PolyNova has received $100,000 in seed funding to transition the technology from the lab to the marketplace. Half of the funds were provided by the Accelerate Long Island Seed Fund; the other by the Long Island Emerging Technologies Fund.

“This award will help further advance this technology down the regulatory pathway, as well as develop business and marketing strategies to leverage additional funding,” said Slepian. “Development of a safe, effective and durable percutaneous heart valve made of novel, clot-resistant polymeric materials will expand the availability of this therapy to patients both in developed countries as well as in underserved areas worldwide.” 

Currently, TAVR technology uses a valve made with bovine tissue and carries a risk of blood clots.

According to David Allen, vice president of Tech Launch Arizona: “All of the elements of the venture – from the partnership it was founded upon to its goals of making these therapies more accessible – speak to the University of Arizona’s Never Settle strategic plan, which, under the leadership of President Ann Weaver Hart, prioritizes innovating new solutions that impact society and partnering with people and organizations to bring such novel inventions and ideas to the world through commercial pathways.” 

PolyNova, located in Stony Brook, N.Y., was co-founded by Slepian and collaborators Danny Bluestein and Thomas E. Claiborne of Stony Brook University. 

For more information: http://uanews.org/story/slepian-led-startup-targets-paradigm-shift-in-heart-valve-surgery

Related Content

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days
News | Heart Valve Technology | June 11, 2019
June 11, 2019 — Abbott recently announced positive late-breaking data from its TRILUMINATE...
DSM and SAT Partnering to Develop Next-Generation, Cost-Effective Heart Valve
News | Heart Valve Technology | June 04, 2019
Royal DSM recently announced a collaboration with Strait Access Technologies (SAT), to develop the world’s first...

The MitraClip is one example of a transcatheter mitral valve repair or replacement (TMVR) device used in the structural heart repair program at Henry Ford Hospital.

Podcast | Heart Valve Technology | May 31, 2019
Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of
Illustration showing the catheter steps for the LAMPOON procedure designed to prevent left ventricular outflow tract (LVOT) obstruction . From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Figure 1: Illustration showing the catheter steps for the LAMPOON procedure. From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Feature | Heart Valve Technology | May 22, 2019
Researchers at the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH
Edwards Announces Research Milestones for Pascal Transcatheter Mitral Valve Program
News | Heart Valve Technology | May 22, 2019
Edwards Lifesciences Corp. announced strategic clinical and regulatory milestones for its Edwards Pascal transcatheter...
Videos | Heart Valve Technology | May 20, 2019
A demonstration of how to calculate the neo-left ventricular outflow tract (neo-LVOT) on CT imaging for a transcathet
Study Finds TAVR Can Be Considered for Patients in All Surgical Risk Classes
News | Heart Valve Technology | May 08, 2019
Transcatheter aortic valve replacement (TAVR) has been studied as an alternative to surgical aortic valve replacement...
Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge...
New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
Overlay Init